DISCLAIMER

The contents of the presentations above are designed for educational and scientific exchange purposes and are not promotional. They may contain information on investigational products or investigational uses of approved products. No conclusions regarding safety and/or efficacy for such investigational products or uses may be made.

 
SUMMARY

This retrospective biomarker analysis from the Phase 1/1b AdvanTIG‑105 study evaluated associations between baseline biomarkers and clinical outcomes in treatment‑naïve patients with metastatic PD‑L1–positive non‑small cell lung cancer treated with the investigational combination of ociperlimab plus tislelizumab. Patients in cohort 3 (n=46) and cohort 10 (n=68) received ociperlimab at varying doses combined with tislelizumab. Baseline tumor tissue was assessed for PD‑L1 and TIGIT expression, and gene expression profiling was performed. At the August 2024 data cutoff, median follow‑up was 19.7 months for cohort 3 and 9.8 months for cohort 10. Higher PD‑L1 expression (≥25%), higher TIGIT expression (≥5%), and PD‑L1/TIGIT double‑high status were associated with trends toward higher overall response rates and longer progression‑free survival, with more pronounced trends in non‑squamous versus squamous disease. Anti‑TIGIT–related gene expression signatures were also associated with trends toward longer progression‑free survival, primarily in non‑squamous non‑small cell lung cancer.

 
ClinicalTrials.gov ID: NCT04047862